Atrium Therapeutics (RNA) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Veraxa Biotech is the larger company by market cap ($154.1 million vs $141.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNA | VRXA |
|---|---|---|
| Share price | $8.26 | $1.09 |
| Market cap | $141.29M | $154.13M |
| 1-day change | +4.16% | -9.17% |
| YTD return | — | -89.78% |
| 1-year return | — | -89.58% |
| EPS (TTM) | $-5.44 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.77 | $27.36 |
| 52-week low | $7.63 | $1.04 |
| Distance from 52-week high | -50.75% | -96.02% |
| Analyst consensus | none | — |
| Avg. price target upside | +202.66% | — |
| Average volume | 259.35K | 267.20K |
| Shares outstanding | 17.11M | 141.41M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
RNA vs VRXA FAQ
Which is bigger, Atrium Therapeutics or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $154.13M compared with $141.29M for Atrium Therapeutics (RNA).
Are Atrium Therapeutics and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.